文献速递心脑血管急症

Zilebesiran:一种用于高血压的RNA干扰治疗药物

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论单次皮下注射zilebesiran≥200 mg可使高血压患者血清血管紧张素原及24小时动态血压呈剂量依赖性下降,并持续至24周。

该1期研究将高血压患者按2:1随机分配接受单次递增剂量zilebesiran(10、25、50、100、200、400或800 mg)皮下注射或安慰剂,随访24周(A部分);B部分评估800 mg剂量在低盐或高盐饮食下对血压的影响,E部分评估该剂量与厄贝沙坦联合给药的效果。107例入组患者中5例出现轻度、一过性注射部位反应,未报告需医学干预的低血压、高钾血症或肾功能恶化。A部分中,zilebesiran组血清血管紧张素原水平下降与给药剂量相关(第8周r=-0.56;95%CI -0.69至-0.39);单次≥200 mg剂量与第8周收缩压下降>10 mmHg、舒张压下降>5 mmHg相关,昼夜一致并持续至24周。B、E部分结果分别与高盐饮食减弱降压效应、与厄贝沙坦联用增强效应一致。

要点

  • 单次皮下注射zilebesiran≥200 mg者第8周收缩压下降>10 mmHg、舒张压下降>5 mmHg,昼夜一致并持续至24周。
  • 血清血管紧张素原下降与给药剂量相关(第8周r=-0.56;95%CI -0.69至-0.39)。
  • 107例中5例出现轻度、一过性注射部位反应;未报告需医学干预的低血压、高钾血症或肾功能恶化。
  • 高盐饮食与降压效应减弱一致,与厄贝沙坦联用与降压效应增强一致。

适用人群与场景

  • 高血压患者,随机接受单次递增剂量zilebesiran皮下注射或安慰剂,随访24周(A部分)。
  • B部分为800 mg剂量在低盐或高盐饮食条件下的高血压患者;E部分为800 mg剂量与厄贝沙坦联合给药的高血压患者。

处置流程与药物剂量

  • 单次皮下注射zilebesiran 10、25、50、100、200、400或800 mg,或安慰剂,随访24周(A部分研究方案)。
  • ≥200 mg单次皮下注射与第8周收缩压下降>10 mmHg、舒张压下降>5 mmHg相关,并持续至24周。
  • 800 mg剂量在低盐或高盐饮食条件下评估血压效应(B部分)。
  • 800 mg剂量与厄贝沙坦联合给药评估血压效应(E部分)。

研究设计与关键结果

  • 1期研究,107例高血压患者按2:1随机分配接受单次递增剂量zilebesiran(10、25、50、100、200、400或800 mg)皮下注射或安慰剂,随访24周(A部分);B部分评估800 mg剂量在低盐或高盐饮食下对血压的影响,E部分评估该剂量与厄贝沙坦联合给药的效果。
  • 107例中5例出现轻度、一过性注射部位反应;未报告需医学干预的低血压、高钾血症或肾功能恶化。
  • A部分中,zilebesiran组血清血管紧张素原水平下降与给药剂量相关(第8周r=-0.56;95%CI -0.69至-0.39)。
  • 单次zilebesiran≥200 mg与第8周收缩压下降>10 mmHg、舒张压下降>5 mmHg相关,昼夜一致并持续至24周。
  • B部分结果与高盐饮食减弱降压效应一致;E部分结果与厄贝沙坦联用增强降压效应一致。

证据类型、等级与局限

  • 证据类型:1期随机对照研究(A部分为随机、安慰剂对照、单次递增剂量;B、E部分为800 mg剂量下的评估)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐;研究结论为单次皮下注射zilebesiran≥200 mg后血清血管紧张素原水平及24小时动态血压呈剂量依赖性下降,并持续至24周,观察到轻度注射部位反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Angiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis.

METHODS: In this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio to receive either a single ascending subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo and were followed for 24 weeks (Part A). Part B assessed the effect of the 800-mg dose of zilebesiran on blood pressure under low- or high-salt diet conditions, and Part E the effect of that dose when coadministered with irbesartan. End points included safety, pharmacokinetic and pharmacodynamic characteristics, and the change from baseline in systolic and diastolic blood pressure, as measured by 24-hour ambulatory blood-pressure monitoring.

RESULTS: Of 107 patients enrolled, 5 had mild, transient injection-site reactions. There were no reports of hypotension, hyperkalemia, or worsening of renal function resulting in medical intervention. In Part A, patients receiving zilebesiran had decreases in serum angiotensinogen levels that were correlated with the administered dose (r = -0.56 at week 8; 95% confidence interval, -0.69 to -0.39). Single doses of zilebesiran (≥200 mg) were associated with decreases in systolic blood pressure (>10 mm Hg) and diastolic blood pressure (>5 mm Hg) by week 8; these changes were consistent throughout the diurnal cycle and were sustained at 24 weeks. Results from Parts B and E were consistent with attenuation of the effect on blood pressure by a high-salt diet and with an augmented effect through coadministration with irbesartan, respectively.

CONCLUSIONS: Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure were sustained for up to 24 weeks after a single subcutaneous dose of zilebesiran of 200 mg or more; mild injection-site reactions were observed. (Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT03934307; EudraCT number, 2019-000129-39.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023. PMID: 37467498. doi:10.1056/NEJMoa2208391

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。